[1] 曹锋生, 韩继媛.抗胆碱能药防治缺血-再灌注损伤的研究进展[J].医药导报, 2006, 25(9):931. doi: 10.3870/j.issn.1004-0781.2006.09.037
[2] NAUTA RJ, TSIMOYIANNIS E, URIBE M, et al.Oxygen-derived free radical in hepatic ischemia and reperfusion injury in the rat[J].Surg Gynecol Obstet, 1990, 17:120.
[3] 谭敬, 周荣胜, 刘庆波, 等.肝缺血再灌注损伤对大鼠肺组织HO-1和iNOS表达的影响[J].山西医科大学学报, 2015, 46(9):861.
[4] ZHANG WW, XU ZP, CUI YY, et al.Peripheral cholinoceptor antagonist anisodamine counteracts cholinergic adverse effects and facilitates cognitive amelioration of rivastigmine[J].J Neural Transm, 2009, 116(12):1643. doi: 10.1007/s00702-009-0297-7
[5] 孙凯, 杨丽敏.山莨菪碱的药理和临床研究进展[J].世界临床药物, 2010, 31(3):182.
[6] 尹文, 虎晓岷, 袁静, 等.山莨菪碱对多器官功能障碍综合征保护机制的实验研究[J].中国医师杂志, 2004, 6(1):8. doi: 10.3760/cma.j.issn.1008-1372.2004.01.003
[7] 董满库, 崔彦, 陈昌玮, 等.山莨菪碱对大鼠肝脏缺血再灌注损伤保护作用的实验研究[J].中国普外基础与临床杂志, 2001, 8(5):295. doi: 10.3969/j.issn.1007-9424.2001.05.004
[8] 董满库, 崔彦, 周立艳, 等.山莨菪碱对肝脏缺血再灌注后氧自由基的影响[J].世界华人消化杂志, 2003, 11(1):82. doi: 10.3969/j.issn.1009-3079.2003.01.022
[9] 夏春秋, 仲崇俊, 张亚年.山莨菪碱对肺缺血(再灌注损伤的保护机制[J].中国微循环, 2006, 10(3):221.
[10] 杨定华, 张华, 黄毓, 等.HO-1的表达对肝脏缺血再灌注损伤的保护作用[J].南方医科大学学报, 2009, 29(11):2329. doi: 10.3321/j.issn:1673-4254.2009.11.024
[11] MATSUI T, NAGAFUJI T, KUMANISHI T, et al.Role of nitric oxide in pathogenesis underlying ischemic cerebral damage[J].Cellular Molecular Neurob, 1999, 19(1):177.